Biology of the immunomodulatory molecule HLA-G in human liver diseases

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma  André Veillette, Huaijian Guo  Critical Reviews.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Folabomi A. Oladosu, BS, William Maixner, PhD, DDS, Andrea G
Beyond the increasing complexity of the immunomodulatory HLA-G molecule by Edgardo D. Carosella, Benoit Favier, Nathalie Rouas-Freiss, Philippe Moreau,
Immunotherapy of hepatocellular carcinoma
Robert H. Oakley, PhD, John A. Cidlowski, PhD 
Pathological roles of purinergic signaling in the liver
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
Obesity, inflammation, and liver cancer
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
NS5A inhibitors in the treatment of hepatitis C
Hedgehog signaling in the liver
Stem cell therapies for liver failure and cirrhosis
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
The origin of cancer stem cells
Volume 116, Issue 5, Pages (May 1999)
Mesenchymal stromal cell therapy for liver diseases
The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury  Veronika Lukacs-Kornek, Frank Lammert 
Volume 61, Issue 2, Pages (August 2014)
From immunosuppression to tolerance
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Targets for immunotherapy of liver cancer
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Volume 59, Issue 3, Pages (September 2013)
EASL Clinical Practice Guidelines: Wilson’s disease
HLA and Pregnancy: The Paradox of the Fetal Allograft
EASL Recognition Award Recipient 2017: Prof. Giorgina Mieli-Vergani
HCMV jogs the ‘memory’ of NK cells in HBV
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Cannabinoid signaling and liver therapeutics
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
Molecular mechanisms of IgE regulation
Signalling links in the liver: Knitting SOCS with fat and inflammation
Antisense molecules: A new class of drugs
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Silvia Affò, Ramón Bataller  Journal of Hepatology 
HCV animal models and liver disease
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
EpCAM in hepatocytes and their progenitors
Foxa1 and Foxa2 regulate bile duct development in mice
Genetics of hepatocellular carcinoma: The next generation
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Update on glucocorticoid action and resistance
Presentation transcript:

Biology of the immunomodulatory molecule HLA-G in human liver diseases Laurence Amiot, Nicolas Vu, Michel Samson  Journal of Hepatology  Volume 62, Issue 6, Pages 1430-1437 (June 2015) DOI: 10.1016/j.jhep.2015.03.007 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The HLA-G gene, transcripts and proteins. The HLA-G gene consists of 8 exons and 7 introns. Exon 1(E1) encodes the signal peptide, exon 7(E7) is not transcribed and exons 2, 3 (E2, E3) and 4 (E4) encode the a-1 domain, the a-2 domain, and the a-3 domain, respectively; exon 5 (E5) encodes the transmembrane domain and exons 6 (E6) and 7 (E7) encode the cytoplasmic domain, with the final exon, exon 8 corresponding to the 3′ UTR region. The star (∗) in E6 as the symbols in intron 2 and 4 are corresponding to stop codon. The primary transcript produced by transcription of the HLA-G gene undergoes alternative splicing, which generates four isoforms with transmembrane and cytoplasmic domains — HLA-G1, -G2, -G3, -G4 — and three different soluble isoforms —sHLA-G1 or HLA-G5, HLA-G6, and HLA-G7. Journal of Hepatology 2015 62, 1430-1437DOI: (10.1016/j.jhep.2015.03.007) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Cellular source and putative targets of HLA-G in the liver. HLA-G has been reported to be expressed by hepatocytes and mast cells, but there remains some debate concerning its possible expression by hepatocytes. In certain conditions, HLA-G may also be detected in T lymphocytes and in cells of the monocytic lineage, such as monocytes or dendritic cells. The putative target cells of HLA-G are peripheral cells expressing HLA-G receptors (T and B lymphocytes, NK cells, monocytes), T lymphocytes and cells of the monocytic lineage present in inflammatory areas, endothelial cells and mast cells. Journal of Hepatology 2015 62, 1430-1437DOI: (10.1016/j.jhep.2015.03.007) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2015 62, 1430-1437DOI: (10. 1016/j. jhep. 2015 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions